Management of primary Sjögren’s syndrome: recent developments and new classification criteria
- 1 January 2018
- journal article
- review article
- Published by SAGE Publications in Therapeutic Advances in Musculoskeletal Disease
- Vol. 10 (2), 39-54
- https://doi.org/10.1177/1759720x17746319
Abstract
For many years primary Sjögren’s syndrome (pSS) has been considered an orphan disease, since no specific therapies were recognized as being capable of contrasting the development and progression of this disorder. The treatment of oral and ocular features, as well as of the systemic organ involvement, has been entrusted to the joint management of different subspecialty physicians, like ophthalmologists, otolaryngologists, dentists and rheumatologists. These latter subspecialty doctors are usually more involved in the treatment of systemic extraglandular involvement and, to do it, they have long been using the conventional therapies borrowed by the treatment schedules adopted in other systemic autoimmune diseases. The increasing knowledge of the biological pathways that are operative in patients with pSS, and the parallel development of molecular biology technology, have allowed the production and availability of a number of biological agents able to positively act on different disease mechanisms, and thus are candidates for testing in therapeutic trials. Meanwhile, the scientific community has made a great effort to develop new accurate and validated classification criteria and outcome measures to be applied in the selection of patients to be included and monitored in therapeutic studies. Some of the new-generation biotechnological agents have been tested in a number of open-label and randomized controlled trials that have produced in many cases inconclusive or contradictory results. Behind the differences in trial protocols, adopted outcome measures and predefined endpoints, reasons for such unsatisfactory results can be found in the large heterogeneity of clinical subtypes in the examined cohorts. The future challenge for a substantial advancement in the therapeutic approach to pSS could be to identify the pathologic mechanisms, outcome tools and biomarkers that characterize the different subsets of the disease in order to test carefully selected target therapies with the highest probability of success in each different clinical phenotype.Keywords
This publication has 95 references indexed in Scilit:
- Precise probes of type II interferon activity define the origin of interferon signatures in target tissues in rheumatic diseasesProceedings of the National Academy of Sciences, 2012
- Prevalence of interferon type I signature in CD14 monocytes of patients with Sjögren's syndrome and association with disease activity and BAFF gene expressionAnnals Of The Rheumatic Diseases, 2012
- Interleukin-1 Inhibition and Fatigue in Primary Sjögren's Syndrome – A Double Blind, Randomised Clinical TrialPLOS ONE, 2012
- Lymphoid organisation in labial salivary gland biopsies is a possible predictor for the development of malignant lymphoma in primary Sjogren's syndromeAnnals Of The Rheumatic Diseases, 2011
- Lymphotoxin-beta receptor blockade reduces CXCL13 in lacrimal glands and improves corneal integrity in the NOD model of Sjögren's syndromeArthritis Research & Therapy, 2011
- Disturbance of cytokine networks in Sjögren's syndromeArthritis Research & Therapy, 2011
- EULAR Sjögren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjögren's syndromeAnnals Of The Rheumatic Diseases, 2009
- The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosusJCI Insight, 2009
- Janus kinases in immune cell signalingImmunological Reviews, 2009
- Stat proteins and oncogenesisJCI Insight, 2002